Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1990-2-22
|
| pubmed:abstractText |
Seventy previously untreated patients with stage II, III, and IV intermediate- or high-grade lymphoma were treated with methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B) between September 1985 and November 1987. Forty-nine of these patients had diffuse large-cell lymphoma (DLCL), and eight of these patients were human immunodeficiency virus (HIV)-positive. Complete responses were achieved in 54% of all patients and 52% of those with DLCL. With follow-up extending to 36 months, 45% of all DLCL patients are alive, and 50% are still living, if the HIV-positive patients are excluded from the analysis. Chemotherapy was quite toxic. Seventy-five percent of patients had severe mucositis, 42% had peripheral neuropathy, 50% required hospitalization, and 54% experienced leukopenia with a WBC count below 1,000/microL. Seven percent (five patients) died of toxicity related to the chemotherapy. Our analysis of prognostic parameters indicated that B symptoms, a performance status below 80, and, to a lesser extent, elevation of serum lactic acid dehydrogenase (LDH) (in HIV-negative DLCL patients) were associated with an inferior survival. Advanced age, sex, and bulky disease were not found to have a statistically significant effect on survival. Our preliminary results indicate that MACOP-B chemotherapy is an effective regimen for high- and intermediate-grade lymphomas. However, the survival for patients with DLCL treated with MACOP-B is no different than that achieved with previous regimens at our institution.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bleomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0732-183X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
8
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
94-102
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:1688617-Adolescent,
pubmed-meshheading:1688617-Adult,
pubmed-meshheading:1688617-Aged,
pubmed-meshheading:1688617-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1688617-Bleomycin,
pubmed-meshheading:1688617-Bone Marrow Transplantation,
pubmed-meshheading:1688617-Cyclophosphamide,
pubmed-meshheading:1688617-Doxorubicin,
pubmed-meshheading:1688617-Female,
pubmed-meshheading:1688617-Follow-Up Studies,
pubmed-meshheading:1688617-HIV Seropositivity,
pubmed-meshheading:1688617-Humans,
pubmed-meshheading:1688617-Leucovorin,
pubmed-meshheading:1688617-Lymphoma, Non-Hodgkin,
pubmed-meshheading:1688617-Male,
pubmed-meshheading:1688617-Methotrexate,
pubmed-meshheading:1688617-Middle Aged,
pubmed-meshheading:1688617-Neoplasm Staging,
pubmed-meshheading:1688617-Prednisone,
pubmed-meshheading:1688617-Prognosis,
pubmed-meshheading:1688617-Randomized Controlled Trials as Topic,
pubmed-meshheading:1688617-Remission Induction,
pubmed-meshheading:1688617-Time Factors,
pubmed-meshheading:1688617-Vincristine
|
| pubmed:year |
1990
|
| pubmed:articleTitle |
Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
|
| pubmed:affiliation |
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|